Vitality Watch

Dossier pubmed review 09-oct-2026
Narrative review or expert overview without new data

Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus).

Key claim: Oral rapamycin penetrates brain parenchyma and exerts functional CNS mTORC1-inhibitory activity despite unreliable CSF detection, so ADRD trials should use pharmacodynamic surrogates rather than CSF levels as a penetration proxy.

Abstract

Rapamycin, a potent mTORC1 inhibitor, is a leading candidate for treating age-related neurodegenerative disease. Numerous studies demonstrate beneficial effects in a variety of diseases that affect the brain. Yet a persistent belief among researchers is that rapamycin cannot penetrate brain tissue, citing as evidence its absence of detection in cerebrospinal fluid (CSF). This narrative review synthesizes clinical and preclinical evidence challenging this “CSF misconception.” In humans, direct tissue sampling in glioblastoma detects rapamycin in brain at mTORC1-inhibitory concentrations, while functional measures-tumor regression and seizure control in tuberous sclerosis complex, cerebral metabolic preservation on PET in Alzheimer’s disease, increased cerebral blood flow incarriers, and prolonged antidepressant response-demonstrate incontrovertible activity in the brain. In mice, LC-MS/MS confirms dose-dependent brain accumulation, and rapamycin modulates mTORC1 signaling, autophagy, and synaptic, epigenetic, and inflammatory pathways. Rapamycin cannot be reliably detected in CSF because of four pharmacological factors-high lipophilicity with parenchymal sequestration, extreme red-cell and protein binding, P-glycoprotein efflux at the blood-CSF barrier, and assay insensitivity-none of which supports the contention that rapamycin fails to enter brain tissue. We flag the field’s central gap: direct measurement of parent drug in intact human brain parenchyma at therapeutic doses is lacking. CSF concentration is a flawed proxy for rapamycin’s CNS penetration. Alzheimer’s disease and related dementias (ADRD) trials should instead track surrogate markers of mTORC1 inhibition, functional neuroimaging, clinical outcomes, and ADRD fluid biomarkers. These pharmacodynamics measurements are essential to the rational design and interpretation of prevention trials for the aging brain.

Why this matters

A persistent objection to brain-aging and Alzheimer’s trials of oral rapamycin has been that the drug is undetectable in cerebrospinal fluid, which has been read as failure to cross into the CNS. This review reframes CSF as a poor proxy — parenchymal uptake and downstream mTORC1 inhibition occur without matching CSF levels — which shifts how upcoming ADRD rapamycin trials should design their pharmacodynamic endpoints. The gap it closes is interpretive, not empirical: it does not add new outcome data but changes what counts as evidence of brain exposure.

Source

Link

Briefing card

Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus).
Stage: review · pubmed · 09-oct-2026

If you are following oral rapamycin trials in Alzheimer's or brain aging, pharmacodynamic markers of mTORC1 inhibition — not CSF drug levels — are the proposed way to tell whether the drug is acting on your brain.

Oral rapamycin penetrates brain parenchyma and exerts functional CNS mTORC1-inhibitory activity despite unreliable CSF detection, so ADRD trials should use pharmacodynamic surrogates rather than CSF levels as a penetration proxy.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1177/13872877261495936

build build 880 · 2bcef25 · 2026-11-18